Hikma Pharmaceuticals PLC (HKMPY)

41.89 +0.89 (+2.18%) At close: 12:05PM EST

Hikma Pharmaceuticals PLC

1 New Burlington Place
London W1S 2HR
United Kingdom
44 20 7399 2760
https://www.hikma.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 8,700

Key executives

Name	Title	Pay	Exercised	Year born
Engineer Said Samih Taleb Darwazah	Exec. Chairman & CEO	2.71M	N/A	1957
Mr. Mazen Samih Taleb Darwazah	Exec. Vice Chairman & Pres of MENA	2.11M	N/A	1958
Mr. Khalid Waleed Hosny Al Nabilsi	Chief Financial Officer	N/A	N/A	1972
Mr. Hussein Arkhagha	Company Sec. & Chief Counsel	N/A	N/A	N/A
Mr. Bassam Wael Rushdi Kanaan CFA, CPA	Exec. VP of Corp. Devel. and M&A	N/A	N/A	1965
Ms. Susan Ringdal	Exec. VP of Strategic Planning & Global Affairs	N/A	N/A	N/A
Ms. Majda Labadi	Exec. VP of Organisational Devel.	N/A	N/A	N/A
Mr. Riad Mishlawi	Pres of Injectables	N/A	N/A	N/A
Mr. Brian Hoffmann	Pres of Generics	N/A	N/A	N/A
Mr. Samuel Park	Global Head of Intellectual Property (IP) & Gen. Counsel for US	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Corporate governance

Hikma Pharmaceuticals PLC’s ISS governance QualityScore as of 1 October 2022 is 8. The pillar scores are Audit: 8; Board: 10; Shareholder rights: 1; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.